IC
KYMR icon

Ikarian Capital’s Kymera Therapeutics KYMR Stock Holding History

Ikarian Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100,000
Closed -$2.74M – 168
2025
Q1 		$2.74M Buy
+100,000
New +$3.65M 0.34% 61

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Ikarian Capital's KYMR Position: Q2 2022 in Review

Ikarian Capital sold out of Kymera Therapeutics (KYMR) in Q2 2022, closing a stake of 50,000 shares — an estimated $2.12M sold.

Ikarian Capital first reported a position in KYMR in Q1 2022 and held it in 1 quarter. The position peaked at $2.12M in Q1 2022. 100 funds tracked by Wall St. Rank hold KYMR as of Q2 2022.

  • Ikarian Capital reported no remaining Kymera Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Ikarian Capital sold 50,000 Kymera Therapeutics shares in Q2 2022, an estimated $2.12M.
  • Ikarian Capital first reported a position in Kymera Therapeutics in Q1 2022 and held it in 1 quarter.
  • Ikarian Capital's Kymera Therapeutics position peaked at $2.12M in Q1 2022.
  • 100 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.